Dec 16, 2020 7:00 am EST Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Dec 3, 2020 7:00 am EST Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Oct 13, 2020 7:00 am EDT Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
Oct 5, 2020 7:00 am EDT Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
Sep 9, 2020 8:30 am EDT Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
Aug 24, 2020 8:30 am EDT Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering